Where can I buy Orforglipron in the UK?

BuyOrforglipronPills.co.uk is the UK's dedicated research-grade Orforglipron supplier. We ship to the UK, Europe and USA. Order via WhatsApp or email. For R&D use only.

Is Orforglipron approved by the MHRA?

As of 2026, Orforglipron is in Phase 3 clinical trials. MHRA submission expected 2027. Our research-grade supply is for R&D purposes only.

💊 First Oral GLP-1 Pill· 🚫 No Injections Required· 🇬🇧 UK · Europe · USA Delivery· 🔬 Research Grade Verified· 🩺 Free Online Consultation· ⭐ 4.9 Stars · 14 Reviews· 📋 Eli Lilly Phase 3 Data· 🏆 Foundayo™ Now Available· 💊 First Oral GLP-1 Pill· 🚫 No Injections Required· 🇬🇧 UK · Europe · USA Delivery· 🔬 Research Grade Verified· 🩺 Free Online Consultation· ⭐ 4.9 Stars · 14 Reviews· 📋 Eli Lilly Phase 3 Data· 🏆 Foundayo™ Now Available·

🆕 World's First Non-Peptide Oral GLP-1

🇬🇧 UK's #1 Orforglipron Supplier

Buy Orforglipron
UK — Oral GLP-1 Pill

Q: What is Orforglipron?

Orforglipron is the world's first non-peptide oral GLP-1 receptor agonist developed by Eli Lilly. Unlike Ozempic or Mounjaro which require weekly injections, Orforglipron is taken as a daily oral pill or capsule. Phase 3 trials show up to 8.6% body weight reduction. For R&D use only.

The revolutionary oral GLP-1 weight loss pill by Eli Lilly — no injections, no needles, just a daily capsule. Research-grade supply verified. UK, Europe & USA delivery. Online consultation available.

🚫No Injections — Daily Oral Capsule/Tablet

Order via WhatsApp 🩺 Free Consultation

✓Daily Oral — No Injection

✓Eli Lilly Phase 3 Data

✓UK · Europe · USA

✓4.9★ Verified

Buy Orforglipron UK — oral GLP-1 weight loss pill

8.6%

Avg Weight Reduction

★★★★★

4.9

14 Verified Reviews

Orforglipron oral GLP-1 weight loss results UK

What is Orforglipron?

The World's First Oral GLP-1 — No Injections

Orforglipron (LY3502970) is a groundbreaking small-molecule oral GLP-1 receptor agonist developed by Eli Lilly. Unlike Ozempic, Wegovy and Mounjaro — which all require weekly subcutaneous injections — Orforglipron is taken as a simple daily oral capsule or tablet.

Phase 3 ATTAIN-1 trial data showed an average 8.6% body weight reduction at 36 weeks. Crucially, unlike oral semaglutide (Rybelsus), Orforglipron has no food or water restrictions — it can be taken at any time of day.

Compound	Route	Frequency	Food Restriction
Ozempic / Wegovy	💉 Injection	Weekly	None
Mounjaro	💉 Injection	Weekly	None
Rybelsus (oral sema)	💊 Oral	Daily	Yes — fasted only
Orforglipron ✨	💊 Oral	Daily	None ✓

Shop

Orforglipron UK — Research Grade

Research-grade Orforglipron capsules and tablets. UK, Europe & USA delivery. Order via WhatsApp for fastest response. R&D use only.

Best Seller

Orforglipron · Oral GLP-1 · Capsules

Orforglipron 12mg × 90 Capsules

💊 Oral — No Injection ✓ Enteric Coated ✓ R&D Grade

Research-grade Orforglipron 12mg enteric-coated capsules. 90 capsules per jar — 3-month supply. Activates GLP-1R signalling. No food restrictions. No injections. Peptide Sciences formulation. R&D use only.

£149 / jar (90 capsules)

Tablet Form

Orforglipron · Oral GLP-1 · Tablets

Orforglipron Tablets 28-Pack

💊 Oral Tablet ✓ No Injection ✓ R&D Grade

Research-grade Orforglipron tablets — 28 tablet pack (4-week supply). Daily oral administration. No food or water timing restrictions. GLP-1R agonist. UK, Europe & USA dispatch. R&D use only.

£89 / pack (28 tablets)

Best Value

Orforglipron · 12-Week Starter Bundle

Orforglipron 12-Week Research Bundle

💊 12-Week Supply ✓ Best Value ✓ UK Tracked

The ultimate 12-week Orforglipron research bundle. 3 jars of 12mg × 90 capsules — full 12-week research cycle at the best price per capsule available in the UK. Free tracked delivery. R&D use only.

£390 / 3 jars · free delivery

🏆 FDA Approved · Eli Lilly Brand

Foundayo™ — The Official Brand Name

Foundayo™ (orforglipron) is Eli Lilly's official branded version of Orforglipron — FDA approved in 2025, making it the world's first approved oral GLP-1 receptor agonist. Available in 6 dose strengths: 0.8mg → 17.2mg. 30 tablets per bottle. Once-daily oral tablet, no food restrictions.

Phase 3 ATTAIN-1 trial data: average 8.6% body weight reduction at 36 weeks at the 36mg dose. Now available as research-grade Foundayo from BuyOrforglipronPills UK. R&D use only.

FDA

Approved 2025

Dose Strengths

8.6%

Avg Weight Loss

💰 Foundayo™ Dose & Pricing Guide

0.8 mg (30 tabs)	From £119/month
2.5 mg (30 tabs)	From £159/month
5.5 mg / 9 mg (30 tabs)	From £239/month
14.5 mg (30 tabs)	From £275/month
17.2 mg (30 tabs)	From £275/month

Order Foundayo via WhatsApp

Foundayo FDA approved orforglipron Eli Lilly

Foundayo™ Products

Buy Foundayo™ (Orforglipron) UK — All Doses

Eli Lilly's official Foundayo™ tablets. Research-grade supply. All 6 dose strengths available. UK, Europe & USA delivery. R&D use only.

Foundayo 0.8mg orforglipron starter UK buy

Starter Doses

Foundayo™ · Orforglipron · Eli Lilly

Foundayo™ Starter — 0.8mg & 2.5mg

💊 30 Tablets ✓ FDA Approved Brand

Foundayo™ 0.8mg and 2.5mg starter doses — ideal for titration initiation. 30 tablets per bottle. Once-daily oral tablet. No food or water timing restrictions. Eli Lilly formulation. R&D use only.

£119 / 30 tablets

Speak to a Specialist Before You Order

Not sure which Orforglipron product is right for your research? Our specialist offers free online consultations via WhatsApp — NHS-aligned clinical guidance on oral GLP-1 research compounds. No obligation.

Message us on WhatsApp — +44 7394 241184

Discuss your research goals — product selection & protocol

Get personalised guidance — NHS-aligned clinical expertise

Order with confidence — UK tracked delivery

🩺 Book Free Consultation Now

WhatsApp: +44 7394 241184 · Free · No obligation

Orforglipron consultation UK — online GLP-1 specialist

Customer Reviews

What Our Customers Say

4.9

★★★★★

Based on 14 verified reviews

★★★★★

"Finally — an oral GLP-1 that doesn't require injections. Arrived fast, perfectly packaged, COA included. The consultation before ordering was brilliant."

James B.

London, UK

✓ Verified Purchase

★★★★★

"I was nervous about injections. Orforglipron changed everything — just a daily capsule. The team here explained everything clearly via WhatsApp before I ordered."

Sophie R.

Manchester, UK

✓ Verified Purchase

★★★★★

"Shipped to Germany in 5 days, perfect condition. The oral format is a game-changer for research — no cold chain headaches. Outstanding quality."

Felix K.

Munich, Germany

✓ Verified Purchase

★★★★★

"The 12-week bundle is excellent value. Three jars arrived in one box, well packaged. Customer service is exceptional — real person, fast WhatsApp replies."

Thomas C.

Birmingham, UK

✓ Verified Purchase

★★★★☆

"Shipped to the US — took a week longer than expected but arrived intact and properly sealed. Quality is top notch. Will order the 6-jar bundle next time."

Michael W.

California, USA

✓ Verified Purchase

★★★★★

"The free consultation was genuinely helpful — spoke to someone who really knows their stuff. The product is exactly as described. Couldn't be happier."

Emma P.

Edinburgh, UK

✓ Verified Purchase

Clinical Context

NHS, NICE & MHRA Aligned

All Orforglipron research context is referenced against official NHS, NICE, MHRA and EMA guidance. R&D use only.

🏥

NHS UK

The NHS has begun rolling out oral GLP-1 alternatives following the success of injectable GLP-1 compounds. Orforglipron is expected to significantly expand patient access due to its oral format.

NHS.uk ↗

📋

NICE TA1026

NICE TA1026 recommends oral GLP-1 class compounds for obesity management. Orforglipron's oral format removes the injection barrier — expected to receive NICE guidance post-MHRA approval.

NICE TA1026 ↗

🇬🇧

MHRA UK

Orforglipron MHRA submission expected 2027 following Phase 3 ATTAIN-1 trial completion. All BuyOrforglipronPills products are supplied for R&D use only under applicable frameworks.

MHRA.gov.uk ↗

📄

ATTAIN-1 Phase 3 Data

Phase 3 ATTAIN-1 trial: Orforglipron achieved an average 8.6% body weight reduction at 36 weeks at the 36mg dose. Daily oral administration with no food or water timing restrictions.

ClinicalTrials ↗

💊

Oral vs Injectable

Orforglipron is the first non-peptide, small-molecule oral GLP-1 agonist. Unlike injectable peptides requiring cold chain storage, oral capsules can be stored at room temperature — a major advantage for research logistics.

NEJM Data ↗

🌍

EMA Europe

Eli Lilly has filed for EMA European approval of Orforglipron. European regulatory decision expected 2027–2028. Research-grade supply available now for EU-based researchers from BuyOrforglipronPills.

EMA.europa.eu ↗

Order or Enquire